Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 17Thoracic 1Sarcoma 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 111Gastro-enteropancreatic neuroendocrine tumor 19Carcinoma, Neuroendocrine 13Breast Neoplasms 11Stomach Neoplasms 10Neoplasms 10Prostatic Neoplasms 9Pheochromocytoma 9Pancreatic Neoplasms 9Carcinoid Tumor 9Paraganglioma 8Neoplasm Metastasis 8Carcinoma, Hepatocellular 8Adenoma, Islet Cell 8Thyroid Neoplasms 7Sarcoma 7Gastrointestinal Neoplasms 7Esophageal Neoplasms 7Ovarian Neoplasms 6Lung Neoplasms 6Colorectal Neoplasms 6Rectal Neoplasms 5Neuroblastoma 5Melanoma 5Liver Neoplasms 5Colonic Neoplasms 5Anus Neoplasms 5Uterine Cervical Neoplasms 4Gastrointestinal Stromal Tumors 4Gallbladder Neoplasms 4

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Clear-cell metastatic renal cell carcinoma × NET × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡